Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Thoracic 1NET 1

Conditions

Carcinoma, Non-Small-Cell Lung 25Colorectal Neoplasms 21Lung Neoplasms 12Neoplasms 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Head and Neck Neoplasms 6Colonic Neoplasms 6Stomach Neoplasms 5Esophageal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Small Cell Lung Carcinoma 4Rectal Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Peritoneal Neoplasms 3Mesothelioma 3Melanoma 3Carcinoma, Pancreatic Ductal 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Biliary Tract Neoplasms 2Vipoma 1Uterine Cervical Neoplasms 1Tracheal Neoplasms 1Spinocerebellar Degenerations 1

Interventions

Trastuzumab 2vatalanib 1tipifarnib 1pentetreotide 1Thalidomide 1Oxaliplatin 1Leucovorin 1Interleukin-12 Subunit p35 1Interleukin-12 1High-Energy Shock Waves 1Fluorouracil 1Fentanyl 1Everolimus 1Bevacizumab 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrinoma × Fluorouracil × Thoracic × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡